Search

Your search keyword '"Carreira, Patricia E"' showing total 37 results
Start Over Author "Carreira, Patricia E" Publication Year Range Last 3 years
37 results on '"Carreira, Patricia E"'

1. Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a multicenter Spanish study

Author

Antón, Jordi, Mosquera, Juan Manuel, Calzada, Joan, Iglesias, Estíbaliz, Zacarías, Andrea, Olivé, Alejandro, Bittermann, Violeta, Lorenzo, Tania Rodríguez, Remesal, Agustín, Quintana-Ortega, Cristian, Nuño-Nuño, Laura, Robles-Marhuenda, Angel, de Inocencio, Jaime, Martín-López, María, Carreira, Patricia E., Brandy-García, Anahy M., Holgado, Susana, Camacho-Lovillo, Marisol, Ruiz-Román, Alberto, Clemente, Daniel, Narváez, Javier, Campos, José, Sánchez-Manubens, Judith, Bernabéu, Pilar, Graña, Jenaro, Vargas, Carmen, Ortiz-Santamaria, Vera, Castañeda, Santos, de Yébenes, María Jesús García, and Carmona, Loreto

Published
2024
Full Text
View/download PDF

2. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

Author

López-Maraver, Marta, Serrano-Combarro, Ana, Atienza-Mateo, Belén, del Val, Natividad, Casafont-Solé, Ivette, Melero-Gonzalez, Rafael B., Pérez-Linaza, Alba, Calvo Gutiérrez, Jerusalem, Mena-Vázquez, Natalia, Vegas-Revenga, Nuria, Domínguez-Casas, Lucía, Loarce Martos, Jesús, Peralta Ginés, Cilia Amparo, Diez Morrondo, Carolina, Pérez Albaladejo, Lorena, López Sánchez, Rubén, Manzano Canabal, Mª Guadalupe, Brandy-García, Anahy Mª, López Viejo, Patricia, Bonilla, Gema, Maiz-Alonso, Olga, Carrasco-Cubero, Carmen, Garijo Bufort, Marta, Moreno, Mireia, Urruticoechea-Arana, Ana, Ordóñez-Palau, Sergio, González-Montagut, Carmen, Giner Serret, Emilio, De Dios Jiménez De Aberasturi, Juan Ramón, Lozano Morillo, Fernando, Vázquez Rodríguez, Tomás, Carreira, Patricia E, Blanco Madrigal, Juan María, Miguel Ibáñez, Belén, Rodríguez López, Marina, Fernández-Díaz, Carlos, Loricera, Javier, Ferraz-Amaro, Iván, Ferrer-Pargada, Diego, Castañeda, Santos, and Blanco, Ricardo

Published
2024
Full Text
View/download PDF

3. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

Author

Distler, Oliver, Becker, Mike, De Decker, Melissa, Fegatelli, Danilo Alunni, Siegert, Elise, Castellví, Ivan, Cauli, Alberto, Solanki, Kamal, Dagna, Lorenzo, Martin, Mickaël, Moroncini, Gianluca, Poormoghim, Hadi, Kuwana, Masataka, Carreira, Patricia E., Airò, Paolo, Bergmann, Christina, Spierings, Julia, Tanaka, Yoshiya, Selvi, Enrico, Soukup, Tomas, Colalillo, Amalia, Hachulla, Eric, Pellicano, Chiara, Smith, Vanessa, Riemekasten, Gabriela, Zanatta, Elisabetta, Henes, Jörg, Launay, David, Marcoccia, Antonella, Gheorghiu, Ana Maria, Truchetet, Marie-Elise, Iannone, Florenzo, Simeón Aznar, Carmen Pilar, Oliveira, Susana, Vonk, Madelon, Del Galdo, Francesco, and Rosato, Edoardo

Published
2024
Full Text
View/download PDF

4. Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?

Author

Deibel, Elisabeth, Carreira, Patricia E., Vonk, Madelon, del Papa, Nicoletta, Bečvář, Radim, Guillén‐Del‐Castillo, Alfredo, Campochiaro, Corrado, Poormoghim, Hadi, Liem, Sophie, Lazzaroni, Maria‐Grazia, Giollo, Alessandro, Mekinian, Arsène, de Vries‐Bouwstra, Jeska, De Santis, Maria, Balbir‐Gurman, Alexandra, Mihai, Carina, De Luca, Giacomo, Moiseev, Sergey, Zanatta, Elisabetta, Foti, Rosario, Rednic, Simona, Denton, Christopher, Cutolo, Maurizio, Belloli, Laura, Airo, Paolo, Garzanova, Liudmila, Moroncini, Gianluca, İnanç, Murat, Panopoulos, Stylianos, Tandaipan, Jose‐Luis, Chatelus, Emmanuel, Rosato, Edoardo, Kuwana, Masataka, Yavuz, Sule, Alegre‐Sancho, Juan J., Smith, Vanessa, Szűcs, Gabriella, Henes, Joerg, Rodríguez‐Pintó, Ignasi, Atzeni, Fabiola, Spierings, Julia, Truchetet, Marie‐Elise, Milchert, Marcin, Brito de Araujo, Daniel, Riemekasten, Gabriela, Bernardino, Vera, Martin, Thierry, del Galdo, Francesco, Vacca, Alessandra, Mendoza, Fabian, Midtvedt, Øyvind, Murdaca, Giuseppe, Santiago, Tânia, Codullo, Veronica, Cacciapaglia, Fabio, Walker, Ulrich, Brunborg, Cathrine, Tirelli, Francesca, Allanore, Yannick, Furst, Daniel E., Matucci, Marco, Gabrielli, Armando, Distler, Oliver, and Hoffmann‐Vold, Anna‐Maria

Published
2024
Full Text
View/download PDF

5. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Vacca, Alessandra, Giollo, Alessandro, Balbir-Gurman, Alexandra, Gheorghiu, Ana Maria, Marcoccia, Antonella, Herrick, Ariane, Radic, Mislav, Stamenkovic, Bojana, Anic, Branimir, Granel, Brigitte, Ribi, Camillo, Selmi, Carlo Francesco, Carlos de la Puente, Milano, de Souza Müller, Carolina, Denton, Christopher, Kayser, Cristiane, Tanaseanu, Cristina-Mihaela, Majewski, Dominik, Rimar, Doron, Krasowska, Dorota, Veale, Douglas, Walker, Ulrich, Kerzberg, Eduardo, Rezus, Elena, Zanatta, Elisabetta, Siegert, Elise, De Langhe, Ellen, Oksel, Fahrettin, Ingegnoli, Francesca, Cantatore, Francesco Paolo, Szücs, Gabriela, Cuomo, Giovanna, Seskute, Goda, Litinsky, VilniusIra, Castellví, Ivan, Morovic-Vergles, Jadranka, Sibilia, Jean, Henes, Jörg, Solanki, Kamal, Perdan-Pirkmajer, Katja, Herrmann, Kristine, Saketkoo, Lesley Ann, Stamp, Lisa, Mouthon, Luc, Salvador, Maria João, Pozzi, Maria Rosa, Üprus, Maria, Vanthuyne, Marie, Engelhart, Merete, Köhm, Michaela, Iudici, Michele, Inanc, Murat, Fathi, Nihal, Pamuk, Nuri, García de la Peña Lefebv, Paloma, Carreira, Patricia E., Bancel, Dominique Farge, Moroncini, Luca, Montecucco, C., Ancuta, Codrina, Sunderkötter, Cord, Müller-Ladner, Ulf, Rosato, Edoardo, Kucharz, Eugene J., Iannone, Florenzo, Del Galdo, Francesco, Poormoghim, Hadi, Kötter, Ina, Distler, Jörg, Cutolo, Maurizio, Tikly, Mohammed, Damjanov, Nemanja, Hunzelmann, Nicolas, Vlachoyiannopoulos, P., Hasler, Paul, Sarzi Puttini, Piercarlo, Wiland, Piotr, Becvar, Radim, Yavuz, Sule, Zdrojewski, Zbigniew, Pellerito, Raffaele, Foti, Rosario, Ionescu, Ruxandra Maria, Adler, Sabine, Kahl, Sarah, Moiseev, Sergey, Stebbings, Simon, Rednic, Simona, Negrini, Simone, Heitmann, Stefan, Ullman, Susanne, Agachi, Svetlana, Martin, Thierry, Schmeiser, Tim, Riccieri, Valeria, Smith, Vanessa, Bernardino, Vera, Ortiz-Santamaria, Vera, Hsu, Vivien M., Abdel Atty Mohamed, Walid Ahmed, Hoffmann-Vold, Anna-Maria, Brunborg, Cathrine, Airò, Paolo, Ananyeva, Lidia P., Czirják, László, Guiducci, Serena, Hachulla, Eric, Li, Mengtao, Mihai, Carina, Riemekasten, Gabriela, Sfikakis, Petros P., Valentini, Gabriele, Kowal-Bielecka, Otylia, Allanore, Yannick, and Distler, Oliver

Published
2023
Full Text
View/download PDF

6. DLco and echocardiographic parameters in identifying mild pulmonary hypertension in the EUSTAR cohort of systemic sclerosis patients

Author

Colalillo, Amalia, primary, Hachulla, Eric, additional, Pellicano, Chiara, additional, Smith, Vanessa, additional, Bergmann, Christina, additional, Riemekasten, Gabriela, additional, Zanatta, Elisabetta, additional, Henes, Jörg, additional, Launay, David, additional, Marcoccia, Antonella, additional, Gheorghiu, Ana Maria, additional, Truchetet, Marie-Elise, additional, Iannone, Florenzo, additional, Simeón Aznar, Carmen Pilar, additional, Oliveira, Susana, additional, Vonk, Madelon, additional, Del Galdo, Francesco, additional, Rosato, Edoardo, additional, Distler, Oliver, additional, Becker, Mike, additional, De Decker, Melissa, additional, Fegatelli, Danilo Alunni, additional, Siegert, Elise, additional, Castellví, Ivan, additional, Cauli, Alberto, additional, Solanki, Kamal, additional, Dagna, Lorenzo, additional, Martin, Mickaël, additional, Moroncini, Gianluca, additional, Poormoghim, Hadi, additional, Kuwana, Masataka, additional, Carreira, Patricia E., additional, Airò, Paolo, additional, Spierings, Julia, additional, Tanaka, Yoshiya, additional, Selvi, Enrico, additional, and Soukup, Tomas, additional

Published
2024
Full Text
View/download PDF

7. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Matucci Cerinic, Marco, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Kowal Bielecka, Otylia, Cutolo, Maurizio, Cuomo, Giovanna, Kedor, Claudia, Rednic, Simona, Avouac, Jérome, Vlachoyiannopoulos, P., Montecucco, C., Stork, Jiri, Inanc, Murat, Carreira, Patricia E., Novak, Srdan, Czirják, László, Iudici, Michele, Kucharz, Eugene J., Zanatta, Elisabetta, Perdan-Pirkmajer, Katja, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstrand, Roger, Radic, Mislav, Braun-Moscovici, Yolanda, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Vonk, Madelon, Damjanov, Nemanja, Henes, Jörg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Kohm, Michaela, Foeldvari, Ivan, Bajocchi, Gianluigi, Salvador, Maria João, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Ananieva, Lidia P., Herrick, Ariane, Müller-Ladner, Ulf, De Palma, Raffaele, Engelhart, Merete, Szücs, Gabriela, Sobrino Grande, Cristina, Midtvedt, Øyvind, Launay, David, Riccieri, Valeria, Ionescu, Ruxandra Maria, Sha, Ami, Gheorghiu, Ana Maria, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Ullman, Susanne, Alberto von Mühlen, Carlos, Pozzi, Maria Rosa, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Alegre-Sancho, Juan Jose, Herrmann, Kristine, De Langhe, Ellen, Anic, Branimir, Üprus, Maria, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Busquets, Joanna, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Sampaio-Barros, Percival D., Stamp, Lisa, Solanki, Kamal, Veale, Douglas, Loyo, Esthela, Li, Mengtao, Abdel Atty Mohamed, Walid Ahmed, Gigante, Antonietta, Oksel, Fahrettin, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Abignano, Giuseppina, Seskute, Goda, Saketkoo, Lesley Ann, Kerzberg, Eduardo, Bianchi, Washington, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, François, Marcoccia, Antonella, Kahl, Sarah, Hsu, Ivien M., Martin, Thierry, Moiseev, Sergey, Chung, Lorinda S., Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Sommerlatte, Sabine, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Francis, Belloli, Laura, Sfikakis, Petros, Markus, Juliana, Feldman, Gary R, Ramazan, Ana-Maria, Scherer, H.U., Truchetet, Marie-Elise, Lescoat, Alain, Dagna, Lorenzo, van Laar, J.M., Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, Martin, Mickaël, Tanaka, Yoshiya, Elhai, Muriel, Sritharan, Nanthara, Boubaya, Marouane, Balbir-Gurman, Alexandra, Siegert, Elise, Hachulla, Eric, de Vries-Bouwstra, Jeska, Riemekasten, Gabriela, Distler, Jörg H W, Rosato, Edoardo, Del Galdo, Francesco, Mendoza, Fabian A, Furst, Daniel E, de la Puente, Carlos, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Bloch-Queyrat, Coralie, and Allanore, Yannick

Published
2022
Full Text
View/download PDF

8. Recommendations for prevention of infection in systemic autoimmune rheumatic diseases

Author

Rúa-Figueroa Fernández de Larrinoa, Íñigo, Carreira, Patricia E., Brito García, Noé, Díaz del Campo Fontecha, Petra, Pego Reigosa, José María, Gómez Puerta, José A., Ortega-Castro, Rafaela, Tejera Segura, Beatriz, Aguado García, José María, Torre-Cisneros, Julián, Valencia-Martín, José L., Pereda, Claudia Alejandra, Nishishinya-Aquino, María Betina, Otón Sánchez, María Teresa, Silva Fernández, Lucía, Maese Manzano, Jesús, Chamizo Carmona, Eugenio, and Correyero Plaza, María

Published
2022
Full Text
View/download PDF

9. Recomendaciones SER sobre prevención de infección en enfermedades reumáticas autoinmunes sistémicas

Author

Rúa-Figueroa Fernández de Larrinoa, Íñigo, Carreira, Patricia E., Brito García, Noé, Díaz del Campo Fontecha, Petra, Pego Reigosa, José María, Gómez Puerta, José A., Ortega-Castro, Rafaela, Tejera Segura, Beatriz, Aguado García, José María, Torre-Cisneros, Julián, Valencia-Martín, José L., Pereda, Claudia Alejandra, Nishishinya-Aquino, María Betina, Otón Sánchez, María Teresa, Silva Fernández, Lucía, Maese Manzano, Jesús, Chamizo Carmona, Eugenio, and Correyero Plaza, María

Published
2022
Full Text
View/download PDF

11. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

Author

Colalillo, Amalia, Hachulla, Eric, Pellicano, Chiara, Smith, Vanessa, Bergmann, Christina, Riemekasten, Gabriela, Zanatta, Elisabetta, Henes, Jörg, Launay, David, Marcoccia, Antonella, Gheorghiu, Ana Maria, Truchetet, Marie-Elise, Iannone, Florenzo, Simeón Aznar, Carmen Pilar, Oliveira, Susana, Vonk, Madelon, Del Galdo, Francesco, Rosato, Edoardo, Distler, Oliver, Becker, Mike, De Decker, Melissa, Fegatelli, Danilo Alunni, Siegert, Elise, Castellví, Ivan, Cauli, Alberto, Solanki, Kamal, Dagna, Lorenzo, Martin, Mickaël, Moroncini, Gianluca, Poormoghim, Hadi, Kuwana, Masataka, Carreira, Patricia E., Airò, Paolo, Bergmann, Christina, Spierings, Julia, Tanaka, Yoshiya, Selvi, Enrico, and Soukup, Tomas

Abstract

The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a “gray zone” of unclear clinical significance.

Published
2024
Full Text
View/download PDF

12. Does the impact of COVID-19 on patients with systemic sclerosis change over time?

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Deibel, Elisabeth, Carreira, Patricia E, Vonk, Madelon, Del Papa, Nicoletta, Bečvář, Radim, Guillén-Del-Castillo, Alfredo, Campochiaro, Corrado, Poormoghim, Hadi, Liem, Sophie, Lazzaroni, Maria-Grazia, Giollo, Alessandro, Mekinian, Arsène, de Vries-Bouwstra, Jeska, De Santis, Maria, Balbir-Gurman, Alexandra, Mihai, Carina, De Luca, Giacomo, Moiseev, Sergey, Zanatta, Elisabetta, Foti, Rosario, Rednic, Simona, Denton, Christopher, Cutolo, Maurizio, Belloli, Laura, Airo, Paolo, Garzanova, Liudmila, Moroncini, Gianluca, İnanç, Murat, Panopoulos, Stylianos, Tandaipan, Jose-Luis, Chatelus, Emmanuel, Rosato, Edoardo, Kuwana, Masataka, Yavuz, Sule, Alegre-Sancho, Juan J, Smith, Vanessa, Szűcs, Gabriella, Henes, Joerg, Rodríguez-Pintó, Ignasi, Atzeni, Fabiola, Spierings, Julia, Truchetet, Marie-Elise, Milchert, Marcin, Brito de Araujo, Daniel, Riemekasten, Gabriela, Bernardino, Vera, Martin, Thierry, Del Galdo, Francesco, Vacca, Alessandra, Mendoza, Fabian, Midtvedt, Øyvind, Murdaca, Giuseppe, Santiago, Tânia, Codullo, Veronica, Cacciapaglia, Fabio, Walker, Ulrich, Brunborg, Cathrine, Tirelli, Francesca, Allanore, Yannick, Furst, Daniel E, Matucci, Marco, Gabrielli, Armando, Distler, Oliver, Hoffmann-Vold, Anna-Maria, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Deibel, Elisabeth, Carreira, Patricia E, Vonk, Madelon, Del Papa, Nicoletta, Bečvář, Radim, Guillén-Del-Castillo, Alfredo, Campochiaro, Corrado, Poormoghim, Hadi, Liem, Sophie, Lazzaroni, Maria-Grazia, Giollo, Alessandro, Mekinian, Arsène, de Vries-Bouwstra, Jeska, De Santis, Maria, Balbir-Gurman, Alexandra, Mihai, Carina, De Luca, Giacomo, Moiseev, Sergey, Zanatta, Elisabetta, Foti, Rosario, Rednic, Simona, Denton, Christopher, Cutolo, Maurizio, Belloli, Laura, Airo, Paolo, Garzanova, Liudmila, Moroncini, Gianluca, İnanç, Murat, Panopoulos, Stylianos, Tandaipan, Jose-Luis, Chatelus, Emmanuel, Rosato, Edoardo, Kuwana, Masataka, Yavuz, Sule, Alegre-Sancho, Juan J, Smith, Vanessa, Szűcs, Gabriella, Henes, Joerg, Rodríguez-Pintó, Ignasi, Atzeni, Fabiola, Spierings, Julia, Truchetet, Marie-Elise, Milchert, Marcin, Brito de Araujo, Daniel, Riemekasten, Gabriela, Bernardino, Vera, Martin, Thierry, Del Galdo, Francesco, Vacca, Alessandra, Mendoza, Fabian, Midtvedt, Øyvind, Murdaca, Giuseppe, Santiago, Tânia, Codullo, Veronica, Cacciapaglia, Fabio, Walker, Ulrich, Brunborg, Cathrine, Tirelli, Francesca, Allanore, Yannick, Furst, Daniel E, Matucci, Marco, Gabrielli, Armando, Distler, Oliver, and Hoffmann-Vold, Anna-Maria

Published
2024

14. Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients: Analysis From a Multicentric Cohort in Spain

Author

Loarce-Martos, Jesús, Larena, Carmen, Blázquez, M. Ángeles, Joven, Beatriz E., Carreira, Patricia E., Martínez-Barrio, Julia, Monteagudo, Indalecio, López-Longo, Francisco Javier, Ruiz, Lucía, López-Robledillo, Juan Carlos, Almodóvar, Raquel, Llorente, Irene, Tomero, Eva, García-de la Peña, Paloma, Moruno, Henry, Pérez, Ana, Cobo-Ibáñez, Tatiana, Lojo Oliveira, Leticia, Barbadillo, María Carmen, García-De Yébenes, María Jesús, and Nuño-Nuño, Laura

Published
2022
Full Text
View/download PDF

16. Does the impact of COVID‐19 on patients with systemic sclerosis change over time?

Author

Deibel, Elisabeth, primary, Carreira, Patricia E., additional, Vonk, Madelon, additional, del Papa, Nicoletta, additional, Bečvář, Radim, additional, Guillén‐Del‐Castillo, Alfredo, additional, Campochiaro, Corrado, additional, Poormoghim, Hadi, additional, Liem, Sophie, additional, Lazzaroni, Maria‐Grazia, additional, Giollo, Alessandro, additional, Mekinian, Arsène, additional, de Vries‐Bouwstra, Jeska, additional, De Santis, Maria, additional, Balbir‐Gurman, Alexandra, additional, Mihai, Carina, additional, De Luca, Giacomo, additional, Moiseev, Sergey, additional, Zanatta, Elisabetta, additional, Foti, Rosario, additional, Rednic, Simona, additional, Denton, Christopher, additional, Cutolo, Maurizio, additional, Belloli, Laura, additional, Airo, Paolo, additional, Garzanova, Liudmila, additional, Moroncini, Gianluca, additional, İnanç, Murat, additional, Panopoulos, Stylianos, additional, Tandaipan, Jose‐Luis, additional, Chatelus, Emmanuel, additional, Rosato, Edoardo, additional, Kuwana, Masataka, additional, Yavuz, Sule, additional, Alegre‐Sancho, Juan J, additional, Smith, Vanessa, additional, Szűcs, Gabriella, additional, Henes, Joerg, additional, Rodríguez‐Pintó, Ignasi, additional, Atzeni, Fabiola, additional, Spierings, Julia, additional, Truchetet, Marie‐Elise, additional, Milchert, Marcin, additional, Brito de Araujo, Daniel, additional, Riemekasten, Gabriela, additional, Bernardino, Vera, additional, Martin, Thierry, additional, del Galdo, Francesco, additional, Vacca, Alessandra, additional, Mendoza, Fabian, additional, Midtvedt, Øyvind, additional, Murdaca, Giuseppe, additional, Santiago, Tânia, additional, Codullo, Veronica, additional, Cacciapaglia, Fabio, additional, Walker, Ulrich, additional, Brunborg, Cathrine, additional, Tirelli, Francesca, additional, Allanore, Yannick, additional, Furst, Daniel E., additional, Matucci, Marco, additional, Gabrielli, Armando, additional, Distler, Oliver, additional, and Hoffmann‐Vold, Anna‐Maria, additional

Published
2023
Full Text
View/download PDF

17. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

Author

Lescoat, Alain, Huang, Suiyuan, Carreira, Patricia E, Siegert, Elise, de Vries-Bouwstra, Jeska, Distler, Jörg H W, Smith, Vanessa, Del Galdo, Francesco, Anic, Branimir, Damjanov, Nemanja, Rednic, Simona, Ribi, Camillo, Bancel, Dominique Farge, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Khanna, Dinesh, Allanore, Yannick, EUSTAR collaborators, et al, and University of Zurich

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health
Published
2023

18. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, Rosaria, primary, Ramirez, Giuseppe Alvise, additional, Barreira, Sofia C., additional, Cardamone, Chiara, additional, Triggianese, Paola, additional, Aguilera, Silvia, additional, Andersen, Jeanette, additional, Avcin, Tadej, additional, Benistan, Karelle, additional, Bertsias, George, additional, Bortoluzzi, Alessandra, additional, Bouillot, Coralie, additional, Bulina, Inita, additional, Burmester, Gerd R., additional, Callens, Steven, additional, Carreira, Patricia E., additional, Cervera, Ricard, additional, Cutolo, Maurizio, additional, Damian, Laura, additional, Della-Torre, Emanuel, additional, Faria, Raquel, additional, Fonseca, João E., additional, Galetti, Ilaria, additional, Hachulla, Eric, additional, Iaccarino, Luca, additional, Jacobsen, Søren, additional, Khmelinskii, Nikita, additional, Limper, Maarten, additional, Marinello, Diana, additional, Meyer, Alain, additional, Moroncini, Gianluca, additional, Nagy, Gyorgy, additional, Olesinska, Marzena, additional, Pamfil, Cristina, additional, Pileckyte, Margarita, additional, Pistello, Mauro, additional, Rednic, Simona, additional, Richez, Christophe, additional, Romão, Vasco C., additional, Schneider, Matthias, additional, Sciascia, Savino, additional, Scirè, Carlo Alberto, additional, Simonini, Gabriele, additional, Smith, Vanessa, additional, Sulli, Alberto, additional, Tani, Chiara, additional, Tas, Sander W., additional, Tincani, Angela, additional, Vonk, Madelon C., additional, Tektonidou, Maria, additional, and Mosca, Marta, additional

Published
2023
Full Text
View/download PDF

19. Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort

Author

Hughes, Michael; https://orcid.org/0000-0003-3361-4909, Huang, Suiyuan, Alegre-Sancho, Juan Jose, Carreira, Patricia E, Engelhart, Merete, Hachulla, Eric; https://orcid.org/0000-0001-7432-847X, Henes, Joerg, Kerzberg, Eduardo, Pozzi, Maria Rosa, Riemekasten, Gabriela, Smith, Vanessa; https://orcid.org/0000-0001-6271-7945, Szücs, Gabriella, Vanthuyne, Marie, Zanatta, Elisabetta, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Gabrielli, Armando G, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, Steen, Virginia D, Khanna, Dinesh; https://orcid.org/0000-0003-1412-4453, Hughes, Michael; https://orcid.org/0000-0003-3361-4909, Huang, Suiyuan, Alegre-Sancho, Juan Jose, Carreira, Patricia E, Engelhart, Merete, Hachulla, Eric; https://orcid.org/0000-0001-7432-847X, Henes, Joerg, Kerzberg, Eduardo, Pozzi, Maria Rosa, Riemekasten, Gabriela, Smith, Vanessa; https://orcid.org/0000-0001-6271-7945, Szücs, Gabriella, Vanthuyne, Marie, Zanatta, Elisabetta, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Gabrielli, Armando G, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, Steen, Virginia D, and Khanna, Dinesh; https://orcid.org/0000-0003-1412-4453

Abstract

OBJECTIVES: The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. METHODS: We developed and tested three conceptual scenarios of late (>5 years after 1st non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥ 5 units or ≥ 25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19,115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1,043) patients who had lcSSc or dcSSc at baseline. RESULTS: One-fifth of patients among the whole cohort (n = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. CONCLUSIONS: Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.

Published
2023

20. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Elhai, Muriel, primary, Sritharan, Nanthara, additional, Boubaya, Marouane, additional, Balbir-Gurman, Alexandra, additional, Siegert, Elise, additional, Hachulla, Eric, additional, de Vries-Bouwstra, Jeska, additional, Riemekasten, Gabriela, additional, Distler, Jörg H W, additional, Rosato, Edoardo, additional, Del Galdo, Francesco, additional, Mendoza, Fabian A, additional, Furst, Daniel E, additional, de la Puente, Carlos, additional, Hoffmann-Vold, Anna-Maria, additional, Gabrielli, Armando, additional, Distler, Oliver, additional, Bloch-Queyrat, Coralie, additional, Allanore, Yannick, additional, Matucci Cerinic, Marco, additional, Walker, Ulrich, additional, Iannone, Florenzo, additional, Jordan, Suzana, additional, Becvar, Radim, additional, Kowal Bielecka, Otylia, additional, Cutolo, Maurizio, additional, Cuomo, Giovanna, additional, Kedor, Claudia, additional, Rednic, Simona, additional, Avouac, Jérome, additional, Vlachoyiannopoulos, P., additional, Montecucco, C., additional, Stork, Jiri, additional, Inanc, Murat, additional, Carreira, Patricia E., additional, Novak, Srdan, additional, Czirják, László, additional, Iudici, Michele, additional, Kucharz, Eugene J., additional, Zanatta, Elisabetta, additional, Perdan-Pirkmajer, Katja, additional, Coleiro, Bernard, additional, Moroncini, Gianluca, additional, Farge Bancel, Dominique, additional, Airò, Paolo, additional, Hesselstrand, Roger, additional, Radic, Mislav, additional, Braun-Moscovici, Yolanda, additional, Lo Monaco, Andrea, additional, Hunzelmann, Nicolas, additional, Pellerito, Raffaele, additional, Giollo, Alessandro, additional, Morovic-Vergles, Jadranka, additional, Denton, Christopher, additional, Vonk, Madelon, additional, Damjanov, Nemanja, additional, Henes, Jörg, additional, Ortiz Santamaria, Vera, additional, Heitmann, Stefan, additional, Krasowska, Dorota, additional, Hasler, Paul, additional, Kohm, Michaela, additional, Foeldvari, Ivan, additional, Bajocchi, Gianluigi, additional, Salvador, Maria João, additional, Stamenkovic, Bojana, additional, Selmi, Carlo Francesco, additional, Tikly, Mohammed, additional, Ananieva, Lidia P., additional, Herrick, Ariane, additional, Müller-Ladner, Ulf, additional, De Palma, Raffaele, additional, Engelhart, Merete, additional, Szücs, Gabriela, additional, Sobrino Grande, Cristina, additional, Midtvedt, Øyvind, additional, Launay, David, additional, Riccieri, Valeria, additional, Ionescu, Ruxandra Maria, additional, Sha, Ami, additional, Gheorghiu, Ana Maria, additional, Sunderkötter, Cord, additional, Ingegnoli, Francesca, additional, Mouthon, Luc, additional, Smith, Vanessa, additional, Cantatore, Francesco Paolo, additional, Ullman, Susanne, additional, Alberto von Mühlen, Carlos, additional, Pozzi, Maria Rosa, additional, Eyerich, Kilian, additional, Wiland, Piotr, additional, Vanthuyne, Marie, additional, Alegre-Sancho, Juan Jose, additional, Herrmann, Kristine, additional, De Langhe, Ellen, additional, Anic, Branimir, additional, Üprus, Maria, additional, Yavuz, Sule, additional, Granel, Brigitte, additional, de Souza Müller, Carolina, additional, Busquets, Joanna, additional, Agachi, Svetlana, additional, Stebbings, Simon, additional, Mathieu, D'Alessandro, additional, Sampaio-Barros, Percival D., additional, Stamp, Lisa, additional, Solanki, Kamal, additional, Veale, Douglas, additional, Loyo, Esthela, additional, Li, Mengtao, additional, Abdel Atty Mohamed, Walid Ahmed, additional, Gigante, Antonietta, additional, Oksel, Fahrettin, additional, Tanaseanu, Cristina-Mihaela, additional, Foti, Rosario, additional, Ancuta, Codrina, additional, Maurer, Britta, additional, van Laar, Jacob, additional, Kayser, Cristiane, additional, Fathi, Nihal, additional, García de la Peña Lefebvre, Paloma, additional, Sibilia, Jean, additional, Litinsky, Ira, additional, Abignano, Giuseppina, additional, Seskute, Goda, additional, Saketkoo, Lesley Ann, additional, Kerzberg, Eduardo, additional, Bianchi, Washington, additional, Castellví, Ivan, additional, Limonta, Massimiliano, additional, Rimar, Doron, additional, Couto, Maura, additional, Spertini, François, additional, Marcoccia, Antonella, additional, Kahl, Sarah, additional, Hsu, Ivien M., additional, Martin, Thierry, additional, Moiseev, Sergey, additional, Chung, Lorinda S., additional, Schmeiser, Tim, additional, Majewski, Dominik, additional, Zdrojewski, Zbigniew, additional, Martínez-Barrio, Julia, additional, Bernardino, Vera, additional, Sommerlatte, Sabine, additional, Levy, Yair, additional, Rezus, Elena, additional, Nuri Pamuk, Omer, additional, Sarzi Puttini, Piercarlo, additional, Poormoghim, Hadi, additional, Kötter, Ina, additional, Gaches, Francis, additional, Belloli, Laura, additional, Sfikakis, Petros, additional, Markus, Juliana, additional, Feldman, Gary R, additional, Ramazan, Ana-Maria, additional, Scherer, H.U., additional, Truchetet, Marie-Elise, additional, Lescoat, Alain, additional, Dagna, Lorenzo, additional, van Laar, J.M., additional, Rudnicka, Lidia, additional, Oliveira, Susana, additional, Atzeni, Fabiola, additional, Kuwana, Masataka, additional, Mekinian, Arsene, additional, Martin, Mickaël, additional, and Tanaka, Yoshiya, additional

Published
2022
Full Text
View/download PDF

21. Clinical characteristics of juvenile onset systemic sclerosis patients from the juvenile scleroderma inception cohort compared to adult age juvenile-onset patients from EUSTAR. Are these differences suggesting risk for mortality?

Author

Foeldvari, Ivan, Klotsche, Jens, Carreira, Patricia E., Kasapcopur, Ozgur, Adrovic, Amra, Torok, Kathryn, Airò, Paolo, Iannone, Florenzo, Allanore, Yannick, Balbir-Gurman, Alexandra, Schmeiser, Tim, Sztajnbok, Flavio, Terreri, Maria Teresa, Stanevicha, Valda, Anton, Jordi, Feldman, Brian, Khubchandani, Raju, Alexeeva, Ekaterina, Johnson, Sindhu, Katsicas, Maria, Sawhney, Sujata, Smith, Vanessa, Appenzeller, Simone, Avcin, Tadey, Campochiaro, Corrado, De Vries-Bouwstra, Jeska, Kostik, Mikhail, Lehman, Thomas, Marrani, Edoardo, Schonenberg, Dieneke, Sifuentes-Giraldo, W.-Alberto, Vasquez-Canizares, Natalia, Janarthanan, Mahesh, Malcova, Hana, Moll, Monika, Nemcova, Dana, Patwardhan, Anjali, Santos, Maria Jose, Seskute, Goda, Truchetet, Marie-Elise, Veale, Douglas, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, and Distler, Oliver

Subjects
Medicine and health
Abstract

Introduction: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease with a prevalence of 3 in 1,000,000 children. Information on long-term development of organ involvement and clinical characteristics of jSSc patients in adulthood are lacking. It was believed that patients in adult cohorts [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

22. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.

Author

Iudici, Michele, Mongin, Denis, Siegert, Elise, Carreira, Patricia E, Distler, Jörg, Henes, Jörg, Zanatta, Elisabetta, Hachulla, Eric, Luca, Giacomo De, Müller, Carolina de Souza, Santiago, Tânia, Tandaipan, José-Luis, Bianchi, Breno Valdetaro, Santis, Maria De, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Courvoisier, Delphine Sophie, and collaborators, EUSTAR

Subjects
THERAPEUTIC use of glucocorticoids, MULTIVARIATE analysis, SYSTEMIC scleroderma, REGRESSION analysis, TREATMENT effectiveness, DRUG prescribing, DISEASE prevalence, DESCRIPTIVE statistics, PHYSICIAN practice patterns
Abstract

Objectives To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries. Methods We included patients with SSc having a visit recorded in the EUSTAR database from January 2013 onward. We analysed the prevalence and the main features of GCs users, their exposure to GCs over time, and their GCs dosages. Multivariable linear regression was used to analyse the factors identified as associated with GCs intake duration. Time trends, and variations in GCs utilization across recruiting countries were explored. Missing data were imputed using multiple imputation with chained equations. Results The 9819 patients included were mostly females (85%), the majority had lcSSc (73%), and the median age was 58 years. At baseline, 34% of patients (n  = 2769/8109) (48% dcSSc vs 29% lcSSc) were on GCs, and the median dose was 7.5 mg/day. GCs users were more frequently males and anti-Scl70 positive, and more commonly had dcSSc and more severe disease. On average, GCs users spent 25% of their follow-up time (median 33.2 months) on GCs, with no significant between-subsets difference. Notably, 33% (n  = 971/2959) and 22% (n  = 647/2959) of patients followed up for >1 year had received GCs for >6 and >12 months, respectively. Multivariable analysis showed that patient and disease characteristics poorly explained the variability in GCs exposure (adjusted- R 2 = 0.06, P  < 0.001). GCs utilization varied within and across countries, and gradually decreased over time (36% in 2013 vs 23% in 2018). Conclusions GCs are widely and long-term prescribed in SSc, with significant between-countries and within-country differences. A gradual decrease in their utilization has been observed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort.

Author

Hughes, Michael, Huang, Suiyuan, Alegre-Sancho, Juan Jose, Carreira, Patricia E, Engelhart, Merete, Hachulla, Eric, Henes, Joerg, Kerzberg, Eduardo, Pozzi, Maria Rosa, Riemekasten, Gabriela, Smith, Vanessa, Szücs, Gabriella, Vanthuyne, Marie, Zanatta, Elisabetta, Distler, Oliver, Gabrielli, Armando G, Hoffmann-Vold, Anna-Maria, Steen, Virginia D, Khanna, Dinesh, and Collaborators, EUSTAR

Subjects
SKIN diseases, DISEASE progression, SKIN, FIBROSIS, SYSTEMIC scleroderma, CONCEPTUAL structures, LONGITUDINAL method, DISEASE complications
Abstract

Objectives The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. Methods We developed and tested three conceptual scenarios of late (>5 years after first non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥5 units or ≥25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19 115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1043) patients who had lcSSc or dcSSc at baseline. Results One-fifth of patients among the whole cohort (n  = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n  = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within the 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. Conclusions Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Retrotransposon instability dominates the acquired mutation landscape of mouse induced pluripotent stem cells

Author

Gerdes, Patricia, primary, Lim, Sue Mei, additional, Ewing, Adam D., additional, Larcombe, Michael R., additional, Chan, Dorothy, additional, Sanchez-Luque, Francisco J., additional, Walker, Lucinda, additional, Carleton, Alexander L., additional, James, Cini, additional, Knaupp, Anja S., additional, Carreira, Patricia E., additional, Nefzger, Christian M., additional, Lister, Ryan, additional, Richardson, Sandra R., additional, Polo, Jose M., additional, and Faulkner, Geoffrey J., additional

Published
2022
Full Text
View/download PDF

25. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

Author

Salgado, Eva, primary, Romera-Baurés, Montserrat, additional, Beltran-Catalan, Emma, additional, Naredo, Esperanza, additional, Carreira, Patricia E, additional, Garcia-Vivar, Mariluz, additional, Moreno-Muelas, Jose V, additional, Boteanu, Alina, additional, Calvo-Penades, Inma, additional, Sellas-Fernandez, Agusti, additional, Valero, Marta, additional, and Gomez-Reino, Juan J, additional

Published
2022
Full Text
View/download PDF

26. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

Author

Iudici, Michele, Mongin, Denis, Siegert, Elise, Carreira, Patricia E, Distler, Jörg, Henes, Jörg, Zanatta, Elisabetta, Hachulla, Eric, De Luca, Giacomo, Müller, Carolina de Souza, Santiago, Tânia, Tandaipan, José-Luis, Bianchi, Breno Valdetaro, De Santis, Maria, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Courvoisier, Delphine Sophie, Giovanna Cuomo, Gianluca Moroncini, Jiri Stork, Fiorenzo Iannone, Ulrich Walker, Eugenia Bertoldo, Dorota Krasowska, Maria João Salvador, Mohammed Tikly, Valeria Riccieri, Ami Sha, Ana Maria Gheorghiu, Cord Sunderkötter, Francesca Ingegnoli, Luc Mouthon, Vanessa Smith, Francesco Paolo Cantatore, Kilian Eyerich, Piotr Wiland, Marie Vanthuyne, Branimir Anic, Maria Üprus, Brigitte Granel, Alessandra Vacca, Cristina-Mihaela Tanaseanu, Paloma García de la Peña Lefebvre, Jean Sibilia, Ira Litinsky, Lesley Ann Saketkoo, Eduardo Kerzberg, Massimiliano Limonta, Doron Rimar, Petros Sfikakis, Maurizio Cutolo, Rosario Foti, Srdan Novak, Mislav Radic, Raffaele Pellerito, Carlo Francesco Selmi Rozzano, Lidia P Ananieva, Gabriela Szűcs, Carlos de la Puente, Ruxandra Maria Ionescu, Maria Rosa Pozzi, Juan Jose Alegre-Sancho, Kristine Herrmann, Ellen De Langhe, Sule Yavuz Altunizade, Svetlana Agachi, Douglas Veale, Esthela Loyo, Mengtao Li, Edoardo Rosato, Britta Maurer, Iván Castellví, François Spertini, Kamal Solanki, Nicoletta Del Papa, Gerard Espinosa, László Czirják, Bernard Coleiro, Dominique Farge Bancel, Christopher Denton, Nemanja Damjanov, Vera Ortiz Santamaria Granollers, Michaela Kohm, Bojana Stamenkovic, Yannick Allanore, Paolo Airo, Alexandra Balbir-Gurman, Marco Matucci Cerinic, Gabriela Riemekasten, Stefan Heitmann, Nicolas Hunzelmann, Carlomaurizio Montecucco, Jadranka Morovic-Vergles, Camillo Ribi, Michele, Iudici, Denis, Mongin, Elise, Siegert, Patricia E, Carreira, Jörg, Distler, Jörg, Hene, Elisabetta, Zanatta, Eric, Hachulla, Giacomo, De Luca, Carolina de Souza, Müller, Tânia, Santiago, José-Luis, Tandaipan, Breno Valdetaro, Bianchi, Maria, De Santi, Anna-Maria, Hoffmann-Vold, Armando, Gabrielli, Oliver, Distler, Courvoisier, Sophie, Delphine, Cuomo, Giovanna, Moroncini, Gianluca, Stork, Jiri, Iannone, Fiorenzo, Walker, Ulrich, Bertoldo, Eugenia, Krasowska, Dorota, João Salvador, Maria, Tikly, Mohammed, Riccieri, Valeria, Sha, Ami, Maria Gheorghiu, Ana, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Paolo Cantatore, Francesco, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Anic, Branimir, Üprus, Maria, Granel, Brigitte, Vacca, Alessandra, Tanaseanu, Cristina-Mihaela, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Ann Saketkoo, Lesley, Kerzberg, Eduardo, Limonta, Massimiliano, Rimar, Doron, Sfikakis, Petro, Cutolo, Maurizio, Foti, Rosario, Novak, Srdan, Radic, Mislav, Pellerito, Raffaele, Francesco Selmi Rozzano, Carlo, P Ananieva, Lidia, Szűcs, Gabriela, de la Puente, Carlo, Maria Ionescu, Ruxandra, Rosa Pozzi, Maria, Jose Alegre-Sancho, Juan, Herrmann, Kristine, De Langhe, Ellen, Yavuz Altunizade, Sule, Agachi, Svetlana, Veale, Dougla, Loyo, Esthela, Li, Mengtao, Rosato, Edoardo, Maurer, Britta, Castellví, Iván, Spertini, Françoi, Solanki, Kamal, Del Papa, Nicoletta, Espinosa, Gerard, Czirják, László, Coleiro, Bernard, Farge Bancel, Dominique, Denton, Christopher, Damjanov, Nemanja, Ortiz Santamaria Granollers, Vera, Kohm, Michaela, Stamenkovic, Bojana, Allanore, Yannick, Airo, Paolo, Balbir-Gurman, Alexandra, Matucci Cerinic, Marco, Riemekasten, Gabriela, Heitmann, Stefan, Hunzelmann, Nicola, Montecucco, Carlomaurizio, Morovic-Vergles, Jadranka, and Ribi, Camillo

Subjects
Rheumatology, systemic sclerosis, Pharmacology (medical), epidemiology, glucocorticoid
Abstract

Objectives To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries. Methods We included patients with SSc having a visit recorded in the EUSTAR database from January 2013 onward. We analysed the prevalence and the main features of GCs users, their exposure to GCs over time, and their GCs dosages. Multivariable linear regression was used to analyse the factors identified as associated with GCs intake duration. Time trends, and variations in GCs utilization across recruiting countries were explored. Missing data were imputed using multiple imputation with chained equations. Results The 9819 patients included were mostly females (85%), the majority had lcSSc (73%), and the median age was 58 years. At baseline, 34% of patients (n = 2769/8109) (48% dcSSc vs 29% lcSSc) were on GCs, and the median dose was 7.5 mg/day. GCs users were more frequently males and anti-Scl70 positive, and more commonly had dcSSc and more severe disease. On average, GCs users spent 25% of their follow-up time (median 33.2 months) on GCs, with no significant between-subsets difference. Notably, 33% (n = 971/2959) and 22% (n = 647/2959) of patients followed up for >1 year had received GCs for >6 and >12 months, respectively. Multivariable analysis showed that patient and disease characteristics poorly explained the variability in GCs exposure (adjusted-R2 = 0.06, P Conclusions GCs are widely and long-term prescribed in SSc, with significant between-countries and within-country differences. A gradual decrease in their utilization has been observed.

Published
2022

27. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database

Author

Gigante, Antonietta, Hoffmann-Vold, Anna-Maria, Fegatelli, Danilo Alunni, Gabrielli, Armando, Leodori, Giorgia, Coleiro, Bernard, De Santis, Maria, Dagna, Lorenzo, Alegre-Sancho, Juan Jose, Montecucco, Carlomaurizio, Carreira, Patricia E, Balbir-Gurman, Alexandra, Doria, Andrea, Riemekasten, Gabriela, Airò, Paolo, Distler, Jörg H W, Distler, Oliver, Rosato, Edoardo, EUSTAR collaborators, and University of Zurich

Subjects
Adult, Male, 0301 basic medicine, systemic sclerosis, Scleroderma Renal Crisis, Renal function, 610 Medicine & health, computer.software_genre, Scleroderma, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Rheumatology, Predictive Value of Tests, Risk Factors, medicine, Humans, Pharmacology (medical), In patient, Risk factor, 030203 arthritis & rheumatology, EUSTAR, Creatinine, Scleroderma, Systemic, Database, Proportional hazards model, business.industry, Incidence, 10051 Rheumatology Clinic and Institute of Physical Medicine, glomerular filtration rate, scleroderma renal crisis, Middle Aged, medicine.disease, Pulmonary hypertension, Survival Rate, 030104 developmental biology, chemistry, Female, business, computer, Glomerular Filtration Rate
Abstract

Objectives The study aim was to evaluate the estimated glomerular filtration rate (eGFR), its association with clinical disease and its predictive ability with respect to mortality in SSc patients from the European Scleroderma Trials and Research Group (EUSTAR) database. Methods SSc patients from the EUSTAR database who had items required for the calculation of eGFR at a baseline visit and a second follow-up visit available were included. A cut-off eGFR value of 60 ml/min was chosen for all SSc patients, and 30 ml/min for those with scleroderma renal crisis (SRC). Cox regression and competing risk analysis were performed to evaluate the use of eGFR as a predictive factor of mortality. Results A total of 3650 SSc patients were included in this study. The median serum level of creatinine and the mean of eGFR were 0.8 mg/dl (interquartile range = 0.6–0.9) and 86.6 ± 23.7 ml/min, respectively. The eGFR was significantly lower in patients with pulmonary hypertension. Overall survival (OS) was significantly reduced in SSc patients with eGFR 30 ml/min and those with eGFR Conclusion eGFR represents a predictive risk factor for overall survival in SSc. The eGFR, however, does not represent a risk factor for death in SRC.

Published
2021

29. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire

Author

Becker, Mike O, primary, Dobrota, Rucsandra, additional, Garaiman, Alexandru, additional, Debelak, Rudolf, additional, Fligelstone, Kim, additional, Tyrrell Kennedy, Ann, additional, Roennow, Annelise, additional, Allanore, Yannick, additional, Carreira, Patricia E, additional, Czirják, László, additional, Denton, Christopher P, additional, Hesselstrand, Roger, additional, Sandqvist, Gunnel, additional, Kowal-Bielecka, Otylia, additional, Bruni, Cosimo, additional, Matucci-Cerinic, Marco, additional, Mihai, Carina, additional, Gheorghiu, Ana Maria, additional, Mueller-Ladner, Ulf, additional, Sexton, Joseph, additional, Kvien, Tore K, additional, Heiberg, Turid, additional, and Distler, Oliver, additional

Published
2021
Full Text
View/download PDF

30. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Hoffmann-Vold, Anna-Maria, Brunborg, Cathrine, Airò, Paolo, Ananyeva, Lidia P., Czirják, László, Guiducci, Serena, Hachulla, Eric, Li, Mengtao, Mihai, Carina, Riemekasten, Gabriela, Sfikakis, Petros P., Valentini, Gabriele, Kowal-Bielecka, Otylia, Allanore, Yannick, Distler, Oliver, Vacca, Alessandra, Giollo, Alessandro, Balbir-Gurman, Alexandra, Gheorghiu, Ana Maria, Marcoccia, Antonella, Herrick, Ariane, Radic, Mislav, Stamenkovic, Bojana, Anic, Branimir, Granel, Brigitte, Ribi, Camillo, Selmi, Carlo Francesco, Carlos de la Puente, Milano, de Souza Müller, Carolina, Denton, Christopher, Kayser, Cristiane, Tanaseanu, Cristina-Mihaela, Majewski, Dominik, Rimar, Doron, Krasowska, Dorota, Veale, Douglas, Walker, Ulrich, Kerzberg, Eduardo, Rezus, Elena, Zanatta, Elisabetta, Siegert, Elise, De Langhe, Ellen, Oksel, Fahrettin, Ingegnoli, Francesca, Cantatore, Francesco Paolo, Szücs, Gabriela, Cuomo, Giovanna, Seskute, Goda, Litinsky, VilniusIra, Castellví, Ivan, Morovic-Vergles, Jadranka, Sibilia, Jean, Henes, Jörg, Solanki, Kamal, Perdan-Pirkmajer, Katja, Herrmann, Kristine, Saketkoo, Lesley Ann, Stamp, Lisa, Mouthon, Luc, Salvador, Maria João, Pozzi, Maria Rosa, Üprus, Maria, Vanthuyne, Marie, Engelhart, Merete, Köhm, Michaela, Iudici, Michele, Inanc, Murat, Fathi, Nihal, Pamuk, Nuri, García de la Peña Lefebv, Paloma, Carreira, Patricia E., Bancel, Dominique Farge, Moroncini, Luca, Montecucco, C., Ancuta, Codrina, Sunderkötter, Cord, Müller-Ladner, Ulf, Rosato, Edoardo, Kucharz, Eugene J., Iannone, Florenzo, Del Galdo, Francesco, Poormoghim, Hadi, Kötter, Ina, Distler, Jörg, Cutolo, Maurizio, Tikly, Mohammed, Damjanov, Nemanja, Hunzelmann, Nicolas, Vlachoyiannopoulos, P., Hasler, Paul, Sarzi Puttini, Piercarlo, Wiland, Piotr, Becvar, Radim, Yavuz, Sule, Zdrojewski, Zbigniew, Pellerito, Raffaele, Foti, Rosario, Ionescu, Ruxandra Maria, Adler, Sabine, Kahl, Sarah, Moiseev, Sergey, Stebbings, Simon, Rednic, Simona, Negrini, Simone, Heitmann, Stefan, Ullman, Susanne, Agachi, Svetlana, Martin, Thierry, Schmeiser, Tim, Riccieri, Valeria, Smith, Vanessa, Bernardino, Vera, Ortiz-Santamaria, Vera, Hsu, Vivien M., and Abdel Atty Mohamed, Walid Ahmed

Abstract

Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort.

Published
2023
Full Text
View/download PDF

31. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.

Author

Becker, Mike O., Dobrota, Rucsandra, Garaiman, Alexandru, Debelak, Rudolf, Fligelstone, Kim, Kennedy, Ann Tyrrell, Roennow, Annelise, Allanore, Yannick, Carreira, Patricia E., Czirják, László, Denton, Christopher P., Hesselstrand, Roger, Sandqvist, Gunnel, Kowal-Bielecka, Otylia, Bruni, Cosimo, Matucci-Cerinic, Marco, Mihai, Carina, Gheorghiu, Ana Maria, Mueller-Ladner, Ulf, and Sexton, Joseph

Subjects
RESEARCH, RESEARCH evaluation, RHEUMATOLOGY, RESEARCH methodology, SYSTEMIC scleroderma, DISABILITY evaluation, EVALUATION research, HEALTH surveys, SEVERITY of illness index, COMPARATIVE studies, QUALITY of life, QUESTIONNAIRES, SCLERODERMA (Disease), LONGITUDINAL method, DISEASE complications
Abstract

Objectives: Patient-reported outcome measures (PROMs) are important for clinical practice and research. Given the high unmet need, our aim was to develop a comprehensive PROM for systemic sclerosis (SSc), jointly with patient experts.Methods: This European Alliance of Associations for Rheumatology (EULAR)-endorsed project involved 11 European SSc centres. Relevant health dimensions were chosen and prioritised by patients. The resulting Systemic Sclerosis Impact of Disease (ScleroID) questionnaire was subsequently weighted and validated by Outcome Measures in Rheumatology criteria in an observational cohort study, cross-sectionally and longitudinally. As comparators, SSc-Health Assessment Questionnaire (HAQ), EuroQol Five Dimensional (EQ-5D), Short Form-36 (SF-36) were included.Results: Initially, 17 health dimensions were selected and prioritised. The top 10 health dimensions were selected for the ScleroID questionnaire. Importantly, Raynaud's phenomenon, impaired hand function, pain and fatigue had the highest patient-reported disease impact. The validation cohort study included 472 patients with a baseline visit, from which 109 had a test-retest reliability visit and 113 had a follow-up visit (85% female, 38% diffuse SSc, mean age 58 years, mean disease duration 9 years). The total ScleroID score showed strong Pearson correlation coefficients with comparators (SSc-HAQ, 0.73; Patient's global assessment, Visual Analogue Scale 0.77; HAQ-Disability Index, 0.62; SF-36 physical score, -0.62; each p<0.001). The internal consistency was strong: Cronbach's alpha was 0.87, similar to SSc-HAQ (0.88) and higher than EQ-5D (0.77). The ScleroID had excellent reliability and good sensitivity to change, superior to all comparators (intraclass correlation coefficient 0.84; standardised response mean 0.57).Conclusions: We have developed and validated the EULAR ScleroID, which is a novel, brief, disease-specific, patient-derived, disease impact PROM, suitable for research and clinical use in SSc. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database.

Author

Gigante, Antonietta, Hoffmann-Vold, Anna-Maria, Fegatelli, Danilo Alunni, Gabrielli, Armando, Leodori, Giorgia, Coleiro, Bernard, Santis, Maria De, Dagna, Lorenzo, Alegre-Sancho, Juan Jose, Montecucco, Carlomaurizio, Carreira, Patricia E, Balbir-Gurman, Alexandra, Doria, Andrea, Riemekasten, Gabriela, Airò, Paolo, Distler, Jörg, Distler, Oliver, Rosato, Edoardo, and collaborators, the EUSTAR

Subjects
GLOMERULAR filtration rate, PATIENT aftercare, BLOOD pressure, PREDICTIVE tests, CONFIDENCE intervals, PULMONARY hypertension, MULTIVARIATE analysis, SYSTEMIC scleroderma, PULMONARY artery, RISK assessment, SEX distribution, DESCRIPTIVE statistics, MEDICAL appointments, DEATH, PROPORTIONAL hazards models, CREATININE, DISEASE complications
Abstract

Objectives The study aim was to evaluate the estimated glomerular filtration rate (eGFR), its association with clinical disease and its predictive ability with respect to mortality in SSc patients from the European Scleroderma Trials and Research Group (EUSTAR) database. Methods SSc patients from the EUSTAR database who had items required for the calculation of eGFR at a baseline visit and a second follow-up visit available were included. A cut-off eGFR value of 60 ml/min was chosen for all SSc patients, and 30 ml/min for those with scleroderma renal crisis (SRC). Cox regression and competing risk analysis were performed to evaluate the use of eGFR as a predictive factor of mortality. Results A total of 3650 SSc patients were included in this study. The median serum level of creatinine and the mean of eGFR were 0.8 mg/dl (interquartile range = 0.6–0.9) and 86.6 ± 23.7 ml/min, respectively. The eGFR was significantly lower in patients with pulmonary hypertension. Overall survival (OS) was significantly reduced in SSc patients with eGFR < 60 ml/min compared with patients with eGFR ≥ 60 ml/min [OS at 5 years 0.763 (95% CI: 0.700, 0.814) vs 0.903 (95% CI: 0.883, 0.919; P  < 0.001)]. In multivariable analysis, OS was associated with male gender (P  < 0.01), systolic pulmonary arterial pressure (sPAP) (P  < 0.001) and eGFR (P  < 0.001). The cumulative incidence of deaths due to SSc was associated with increased sPAP (P  < 0.001) and reduced eGFR (P  < 0.05). The OS at 5 years of 53 SRC patients was not significantly different between SSc patients with eGFR > 30 ml/min and those with eGFR <30 ml/min. Conclusion eGFR represents a predictive risk factor for overall survival in SSc. The eGFR, however, does not represent a risk factor for death in SRC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.

Author

Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, Damjanov N, Rednic S, Ribi C, Bancel DF, Hoffmann-Vold AM, Gabrielli A, Distler O, Khanna D, and Allanore Y

Subjects
Female, Male, Humans, Fibrosis, Prognosis, Scleroderma, Systemic complications, Scleroderma, Systemic epidemiology, Scleroderma, Diffuse complications, Scleroderma, Diffuse diagnosis, Scleroderma, Diffuse epidemiology, Lung Diseases, Interstitial complications, Telangiectasis etiology, Telangiectasis complications
Abstract

Importance: Systemic sclerosis (SSc) sine scleroderma (ssSSc) is a subset of SSc defined by the absence of skin fibrosis. Little is known about the natural history and skin manifestations among patients with ssSSc., Objective: To characterize the clinical phenotype of patients with ssSSc compared with patients with limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) within the EUSTAR database., Design, Setting, and Participants: This longitudinal observational cohort study based on the international EUSTAR database included all patients fulfilling the classification criteria for SSc assessed by the modified Rodnan Skin score (mRSS) at inclusion and with at least 1 follow-up visit; ssSSc was defined by the absence of skin fibrosis (mRSS = 0 and no sclerodactyly) at all available visits. Data extraction was performed in November 2020, and data analysis was performed from April 2021 to April 2023., Main Outcomes and Measures: Main outcomes were survival and skin manifestations (onset of skin fibrosis, digital ulcers, telangiectasias, puffy fingers)., Results: Among the 4263 patients fulfilling the inclusion criteria, 376 (8.8%) were classified as having ssSSc (mean [SD] age, 55.3 [13.9] years; 345 [91.8%] were female). At last available visit, in comparison with 708 patients with lcSSc and 708 patients with dcSSc with the same disease duration, patients with ssSSc had a lower prevalence of previous or current digital ulcers (28.2% vs 53.1% in lcSSc; P < .001; and 68.3% in dcSSc; P < .001) and puffy fingers (63.8% vs 82.4% in lcSSc; P < .001; and 87.6% in dcSSc; P < .001). By contrast, the prevalence of interstitial lung disease was similar in ssSSc and lcSSc (49.8% and 57.1%; P = .03) but significantly higher in dcSSc (75.0%; P < .001). Skin telangiectasias were associated with diastolic dysfunction in patients with ssSSc (odds ratio, 4.778; 95% CI, 2.060-11.081; P < .001). The only independent factor for the onset of skin fibrosis in ssSSc was the positivity for anti-Scl-70 antibodies (odds ratio, 3.078; 95% CI, 1.227-7.725; P = .02). Survival rate was higher in patients with ssSSc (92.4%) compared with lcSSc (69.4%; P = .06) and dcSSc (55.5%; P < .001) after up to 15 years of follow-up., Conclusions and Relevance: Systemic sclerosis sine scleroderma should not be neglected considering the high prevalence of interstitial lung disease (>40%) and SSc renal crisis (almost 3%). Patients with ssSSc had a higher survival than other subsets. Dermatologists should be aware that cutaneous findings in this subgroup may be associated with internal organ dysfunction. In particular, skin telangiectasias in ssSSc were associated with diastolic heart dysfunction.

Published
2023
Full Text
View/download PDF

36. Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients: Analysis From a Multicentric Cohort in Spain.

Author

Loarce-Martos J, Larena C, Blázquez MÁ, Joven BE, Carreira PE, Martínez-Barrio J, Monteagudo I, López-Longo FJ, Ruiz L, López-Robledillo JC, Almodóvar R, Llorente I, Tomero E, García-de la Peña P, Moruno H, Pérez A, Cobo-Ibáñez T, Lojo Oliveira L, Barbadillo MC, García-De Yébenes MJ, and Nuño-Nuño L

Subjects
Adult, Cohort Studies, Humans, Longitudinal Studies, Retrospective Studies, Spain epidemiology, Myositis diagnosis, Myositis drug therapy, Myositis epidemiology
Abstract

Methods: This study reviewed the medical records of patients from the REMICAM cohort, a multicentric longitudinal study carried out in patients with IIM, followed up between 1980 and 2014 in 12 hospitals in Madrid, Spain. Patients with definite or probable JPM, JDM, adult DM, and adult PM according to the modified Bohan and Peter criteria were selected. We compared the characteristics between JDM and JPM, and between JIIM and adult IIM., Results: Eighty-six juvenile patients (75 JDMs and 11 JPMs) and 283 adult patients (133 DMs and 150 PMs) were included. Compared with patients with JDM, patients with JPM were older at diagnosis, had more fever and arthritis, and were less frequently treated with disease-modifying antirheumatic drugs (these differences were not statistically significant). Compared with patients with adult DM, those with JDM presented more frequently with calcinosis (33.8% vs 6.9%, p < 0.0001) and had less severe infections (4.3% vs 23.4%, p < 0.0001), malignancies (1.3% vs 25.6%, p < 0.0001), and mortality (3.5% vs 33%, p < 0.0001). Patients with JDM were treated less frequently with azathioprine (10.8% vs 44.7%, p < 0.0001)., Conclusions: Our findings confirm that JIIMs are a heterogeneous group of diseases with relevant differences compared with adult IIMs., Competing Interests: The authors declare no conflict of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

37. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database.

Author

Gigante A, Hoffmann-Vold AM, Alunni Fegatelli D, Gabrielli A, Leodori G, Coleiro B, De Santis M, Dagna L, Alegre-Sancho JJ, Montecucco C, Carreira PE, Balbir-Gurman A, Doria A, Riemekasten G, Airò P, Distler J, Distler O, and Rosato E

Subjects
Adult, Female, Humans, Incidence, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Survival Rate, Glomerular Filtration Rate, Scleroderma, Systemic mortality
Abstract

Objectives: The study aim was to evaluate the estimated glomerular filtration rate (eGFR), its association with clinical disease and its predictive ability with respect to mortality in SSc patients from the European Scleroderma Trials and Research Group (EUSTAR) database., Methods: SSc patients from the EUSTAR database who had items required for the calculation of eGFR at a baseline visit and a second follow-up visit available were included. A cut-off eGFR value of 60 ml/min was chosen for all SSc patients, and 30 ml/min for those with scleroderma renal crisis (SRC). Cox regression and competing risk analysis were performed to evaluate the use of eGFR as a predictive factor of mortality., Results: A total of 3650 SSc patients were included in this study. The median serum level of creatinine and the mean of eGFR were 0.8 mg/dl (interquartile range = 0.6-0.9) and 86.6 ± 23.7 ml/min, respectively. The eGFR was significantly lower in patients with pulmonary hypertension. Overall survival (OS) was significantly reduced in SSc patients with eGFR < 60 ml/min compared with patients with eGFR ≥ 60 ml/min [OS at 5 years 0.763 (95% CI: 0.700, 0.814) vs 0.903 (95% CI: 0.883, 0.919; P < 0.001)]. In multivariable analysis, OS was associated with male gender (P < 0.01), systolic pulmonary arterial pressure (sPAP) (P < 0.001) and eGFR (P < 0.001). The cumulative incidence of deaths due to SSc was associated with increased sPAP (P < 0.001) and reduced eGFR (P < 0.05). The OS at 5 years of 53 SRC patients was not significantly different between SSc patients with eGFR > 30 ml/min and those with eGFR <30 ml/min., Conclusion: eGFR represents a predictive risk factor for overall survival in SSc. The eGFR, however, does not represent a risk factor for death in SRC., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results